<DOC>
	<DOCNO>NCT00005595</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient relapsed refractory Hodgkin 's disease .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Relapsed Refractory Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy arsenic trioxide term rate response ( complete partial remission ) , duration response , relapse free survival , overall survival patient relapse refractory Hodgkin 's disease . II . Evaluate toxicity agent patient population . III . Elucidate mechanism action treatment measure induction apoptosis caspace activation give patient . OUTLINE : This multicenter study . Patients receive arsenic trioxide IV 1-2 hour daily 60 day . After 4-6 week rest , patient receive 5 additional course therapy 25 day follow 4-6 week rest . Patients complete response ( CR ) receive 1 additional course 25 day achieve CR . Treatment continue absence unacceptable toxicity disease progression . Patients follow monthly 6 month , every 2 month 6 month , every 3 month 12 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed refractory Hodgkin 's disease Relapsed prior first line treatment least 2 regimen , : Mechlorethamine , vincristine , procarbazine , prednisone ( MOPP ) Doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) MOPP/ABV Stanford 5 OR Refractory second line regimen , : Mesna , ifosfamide , mitoxantrone , etoposide ( MINE ) Etoposide , methylprednisolone , high dose cytarabine , cisplatin ( ESHAP ) High dose chemotherapy autologous allogeneic stem cell transplantation At least 1 measurable lesion PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Unless document bone marrow involvement : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No prior malignancy within past 5 year except curatively treat basal cell squamous cell carcinoma skin carcinoma situ cervix No concurrent active infection require antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent biologic agents No concurrent monoclonal antibody No concurrent bone marrow transplantation Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>